Page 21 - 74_02

VOL. 74 (2), 181-201, 2008 ARILESTERASA. ASPECTOS METODOLÓGICOS...

cias AGL2001-2398-C03-03 y AGL2005-07204-C02-01/ALI que han
financiado toda la investigación. Así como a la Universidad Complu-
tense de Madrid la concesión de la Beca Predoctoral a Meritxell Nus
Chimeno.

BIBLIOGRAFÍA

(1) HAREL, M.; AHARONI, A.; GAIDUKOV, L.; BRUMSHTEIN, B.; KHERSONSKY, O.; MEGED,
R.; DVIR, H.; RAVELLI, R. B. G.; MCCARTHY, A.; TOKER L. et al. (2004): Structure
(2) and evolution of the serum paraoxonase family of detoxifying and anti-athe-
rosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 412-419.
(3) HAREL, M.; AHARONI, A.; GAIDUKOV, L.; BRUMSHTEIN, B.; KHERSONSKY, O.; MEGED,
(4) R.; DVIR, H.; RAVELLI, R. B. G.; MCCARTHY, A.; TOKER, L. et al. (2004): Corri-
gendum. Structure and evolution of the serum paraoxonase family of detoxi-
(5) fying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11: 1253.
(6) PROTEIN DATA BANK. http://www.rcsb.org/pdb/navbarsearch.do?newSearch=yes
(7) &isAuthorSearch=no&radioset=All&inputQuickSearch=1v04
(8) RENAULT, F.; CHABRIERE, E.; ANDRIEU, J. P.; DUBLET, B.; MASSON, P. and ROCHU,
D. (2006): Tandem purification of two HDL-associated partner proteins in
(9) human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP)
(10) using hydroxyapatite chromatography. J. Chromatog. B. 836: 15-21.
AZARSIZ, E.; KAYIKCIOGLU, M.; PAYZIN, S. and YILDIRIM SOZMEN, E. (2003): PON1
(11) Activities and oxidative markers of LDL in patients with angiographically
proven coronary artery disease. Int. J. Cardiol. 91: 43-51.
WHEELER, J. G.; KEAVNEY, B. D.; WATKINS, H.; COLLINS, R. and DANESH, J. (2004):
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart
disease and 12786 controls: meta-analysis of 43. Lancet. 363: 689.
MACKNESS, B.; DURRINGTON, P. N.; MCELDUFF, P. et al. (2003): Low paraoxonase
activity predicts coronary events in the Caerphilly prospective. Circulation.
107: 2775-2779.
TOMÁS, M.; SENTÍ, M.; GARCÍA-FARIA, F.; VILA, J.; TORRENTS, A.; COVAS, M. and
MARRUGAT, J. (2000): Effect of simvastatin therapy on paraoxonase activity
and related lipoproteins in familial hypercholesterolemic patients. Arterios-
cler. Thromb. Vasc. Biol. 20: 2113-2119.
INOUE, M.; SUEHIRO, T.; NAKAMURA, T.; IKEDA, Y.; KUMON, Y. and HASHIMOTO, K.
(2000): Serum arylesterase/diazoxonase activity and genetic polymorphisms
in patients with type 2 diabetes. Metabolism. 49: 1400-1405.
ABBOTT, C. A.; MACKNESS, M. I.; KUMAR, S. et al. (1995): Serum paraoxonase
activity, concentration, and phenotype distribution in diabetes mellitus and
its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc.
Biol. 15: 1812-1818.
SUTHERLAND, W. H. F.; MANNING, P. J.; DE JONG, S. A.; ALLUM, A. R.; JONES, S.
D. and WILLIAMS, S. M. (2001): Hormone-replacement therapy increases serum

199